Genome Editing Market to Reach USD 32.72B by 2032, Growing at 16.98% CAGR
The global Genome Editing
Market Share, valued at USD 7.99 billion in 2023, is
projected to witness an extraordinary surge, reaching USD 32.72 billion
by 2032, expanding at a Compound Annual Growth Rate (CAGR) of
16.98% during the forecast period of 2024 to 2032. Fueled
by the rapid advancements in gene editing tools, increasing investment in
biotech research, and rising demand for precision medicine, the market is
entering an era of unprecedented growth and innovation.
Market
Overview
Genome editing, also known
as gene editing, refers to the set of technologies that allow scientists to
modify an organism’s DNA with high precision. Emerging as a transformative tool
across therapeutics, agriculture, and biotechnology, genome editing has gained
remarkable traction, particularly due to the popularity and efficiency of CRISPR-Cas9 and
other next-generation platforms like TALENs, ZFNs,
and meganucleases.
Get
Free Sample Report on Genome Editing Market
https://www.snsinsider.com/sample-request/3944
In recent years, genome
editing has been increasingly adopted for treating genetic disorders,
developing gene therapies, creating genetically modified organisms (GMOs), and
improving disease resistance in crops. The market's strong momentum is also
being propelled by regulatory support for clinical trials and increasing
public-private partnerships focused on genomic R&D.
Key
Market Drivers
1. Breakthrough Innovations in CRISPR and Related Technologies
·
The CRISPR-Cas9 system continues to
dominate the market due to its ease of use, accuracy, and cost-effectiveness.
Continued innovation in CRISPR base editing and prime editing is significantly
widening therapeutic applications.
Rising Prevalence of
Genetic and Chronic Diseases
·
Growing incidences of cancer, cardiovascular
diseases, and hereditary conditions such as sickle cell anemia and cystic
fibrosis are pushing demand for genome editing-based therapies.
Increased Funding
for Genomic Research
·
Governments and private organizations
are investing heavily in genomic research, leading to increased development of
gene-editing therapies and diagnostic tools.
Expanding
Applications in Agriculture
·
Gene editing is being widely used to
enhance crop yield, resistance to pests, and environmental tolerance, thereby
bolstering its application beyond healthcare.
Market
Challenges
Despite its promising
growth trajectory, the genome editing market faces certain challenges:
·
Ethical Concerns and
Regulatory Hurdles
·
Ethical debates over human germline
editing and lack of clear regulatory frameworks in several regions continue to
limit broader adoption.
·
Off-Target Effects
·
Precision and safety concerns,
especially related to off-target gene modifications, are impeding rapid
clinical translation of genome editing technologies.
·
High Costs of Equipment and
Services
·
Although CRISPR has lowered barriers
to entry, the overall costs associated with development, trials, and
commercialization of gene editing tools remain significant.
Key
Market Segments
By
Application
· Genetic Engineering
o Cell Line Engineering
o Animal Genetic Engineering
o Plant Genetic Engineering
o Others
· Clinical Applications
o Diagnostics
o Therapy Development
By
Technology
· (CRISPR)/Cas9
· TALENs/MegaTALs
· ZFN
· Meganuclease
· Others
By
Delivery Method
· Ex-vivo
· In-vivo
By
End-use
· Biotechnology and Pharmaceutical Companies
· Academic and Government Research Institutes
· Contract Research Organizations
Key
Players
· Merck KGaA - CRISPR-Cas9 Gene Editing Platform
· Cibus Inc. - Rapid Trait Development System (RTDS)
· Recombinetics - Gene
Editing for Animal Health and Agricultural Biotechnology
· Sangamo Therapeutics - Zinc Finger Nucleases (ZFNs)
· Editas Medicine - EDIT-101 (CRISPR-based Gene Therapy)
· Precision BioSciences - Arcus Gene Editing Platform
· CRISPR Therapeutics - CTX001
(CRISPR-based Therapy for Genetic Disorders)
· Intellia Therapeutics, Inc. - NTLA-2001 (CRISPR-based Therapeutic)
· Caribou Biosciences, Inc. - CRISPR-Cas12a
and CRISPR-Cas9 Technologies
· Cellectis S.A. - TALEN
Gene Editing System
· AstraZeneca - CRISPR
Gene Editing Research Initiatives
· Takara Bio Inc. - Gibson
Assembly and CRISPR/Cas9 Systems
· Horizon Discovery Ltd. (Revvity, Inc.) - GENESIS Gene Editing Services
· Danaher Corporation - EditR (Gene Editing Platform)
· Transposagen Biopharmaceuticals, Inc. - Transposon-based Gene Editing Technologies
· Genscript Biotech Corp - CRISPR
Gene Editing Kits and Services
· New England Biolabs - CRISPR
Enzymes and Tools
Recent
Developments
·
March 2024: Intellia Therapeutics reported promising results from Phase II trials
using CRISPR to treat transthyretin amyloidosis.
·
January 2024: Synthego launched a new line of off-the-shelf CRISPR kits for academic
and industrial labs.
·
November 2023: CRISPR Therapeutics and Vertex Pharmaceuticals filed for regulatory
approval of their gene therapy for sickle cell disease in the U.S. and Europe.
·
August 2023: The Chinese government announced a $2 billion fund to support gene
editing and synthetic biology research.
Future
Outlook
With the evolution of more
refined editing tools, such as base editing and prime
editing, and the increasing clinical success of gene therapies, the genome
editing market is poised to revolutionize modern medicine and biotechnology.
Personalized treatments, once seen as a futuristic dream, are now becoming
mainstream possibilities due to gene editing breakthroughs.
Additionally, as regulatory
clarity improves and ethical concerns are addressed through transparent
frameworks, more players are expected to enter the market, further intensifying
innovation and competition.
Conclusion
The global genome
editing market is on the cusp of a transformation that may redefine
the future of medicine, agriculture, and biological sciences. Backed by
powerful innovations, expanding applications, and strong investor interest, the
industry’s path to USD 32.72 billion by 2032 reflects the
rising confidence in gene editing technologies to cure diseases, feed the
planet, and build sustainable solutions across multiple sectors.
About
US
SNS Insider is one of the
leading market research and consulting agencies that dominates the market research
industry globally. Our company's aim is to give clients the knowledge they
require in order to function in changing circumstances. In order to give you
current, accurate market data, consumer insights, and opinions so that you can
make decisions with confidence, we employ a variety of techniques, including
surveys, video talks, and focus groups around the world.
Contact
Us:
Jagney Dave - Vice
President of Client Engagement
Phone: +1-315 636 4242 (US)
| +44- 20 3290 5010 (UK).
Comments
Post a Comment